Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Introduction: Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers. Methods: We performed a full review of published studies addressing the PK of intravenous β-lactam antibiotics given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only English-language articles reporting studies addressing β-lactam antibiotics that had been described in at least five previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded. Results: A total of 57 studies addressing six different β-lactam antibiotics (meropenem, imipenem, piperacillin, cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl with creatinine clearance was usually reported. Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised in critically ill patients with septic shock. Conclusions: The PK of β-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients. Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Heterogeneity of volume of distribution in litres of β-lactam antibiotics in ICU patients. Open circles: volume of distribution in healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of volume of distribution in the studies.](https://figures.cochat.ai/paper-figures/83611cc812e44433b6b33a2cd391c970/antibiotics-in-critically-ill-patients-a-systematic-review-of-the-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beta-lactam antibiotics may be subject to changes in important pharmacokinetic parameters in the setting of sepsis and septic shock resulting in sub-therapeutic concentrations [230, 231].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Basic & Clinical Biostatistics
Dawson, B. K., & Trapp, R. G. (2004) · Cited by 699
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556 · cited 1×
“Considerable evidence demonstrates that free drug time above bacteria minimal inhibitory concentration (f T > MIC) is the measure of drug exposure most closely linked to the ability of b-lactam antibiotics to kill the target bacteria [4].”
BackgroundThe epidemiology of the systemic inflammatory response
Brun-Buisson, C. (2000) · Intensive Care Medicine · doi:10.1007/s001340051121 · Cited by 534 · cited 1×
“Infection and sepsis, whether community- or hospitalacquired, are important causes of morbidity and mortality in ICU patients [1,2].”
BackgroundFridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Taccone, F. S., Laterre, P.-F., Dugernier, T., Spapen, H., Delattre, I., Wittebole, X., De Backer, D., Layeux, B., Wallemacq, P., Vincent, J.-L., et al. (2010) · Critical Care · doi:10.1186/cc9091 · Cited by 369 · cited 2×
“…= 8 mg/L: bolus 70%, CI 100% CFR for EC: bolus 100%, CI 100% CFR for PA: bolus 40.6%, CI 100% Ceftazidime, 2 g 70% T > 4 × EUCAST breakpoint of PA 28% Taccone et al., 2010 [23] Cefepime, 2 g 70% T > 4 × EUCAST breakpoint of PA 16% Meropenem, 1 g 40% T > 4 × EUCAST breakpoint of PA…”
BackgroundInfluentialRoberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347 · cited 13×
“…± 4.9 6.7 ± 4.2 3.7 ± 1.9 N = 6 Age 65.7 ± 11.2 years Peritonitis Descriptive Karjagin et al., 2008 [25] Meropenem 22.7 13.6 ± 1.3 NR N = 10 Age range 48 to 63 years Severe sepsis Randomized, parallel controlled Roberts et al., 2009 [24] Meropenem Meropenem 30.1 [21.7 to 53.9]e Meropenem 8 [5 to…”
BackgroundMethodInfluentialTherapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Roberts, J. A., Ulldemolins, M., Roberts, M. S., McWhinney, B., Ungerer, J., Paterson, D. L., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.008 · Cited by 334
Pea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327 · cited 1×
“Drugs that distribute essentially in the extracellular fluid (mainly hydrophilic) have low Vd, whilst drugs that have rapid cellular uptake (lipophilic) have high Vd[5,6].”
BackgroundRoberts, J. A., & Lipman, J. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645080-00001 · Cited by 283
Joukhadar, C., Frossard, M., Mayer, B. X., Brunner, M., Klein, N., Siostrzonek, P., Eichler, H. G., & Müller, M. (2001) · Critical Care Medicine · doi:10.1097/00003246-200102000-00030 · Cited by 279 · cited 9×
“-lactam antibioticsa (Continued) CI 100% Ceftazidime 1.5 g tid or 4.5 g/day CI T > 4 × MIC plasma and peritoneum (isolated pathogens) Plasma: bolus dosing 100%, CI 100% Buijk et al., 2002 [74] Peritoneum: bolus 88%, CI 100% Ceftazidime 2 to 6 g/day CI 100% T > 5 × MIC MIC = 8 mg/L (PA break point) Target concentration…”
BackgroundInfluentialA systematic review on clinical benefits of continuous administration of β-lactam antibiotics*
Roberts, J. A., Webb, S., Paterson, D., Ho, K. M., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181a0054d · Cited by 225
Baptista, J. P., Udy, A. A., Sousa, E., Pimentel, J., Wang, L., Roberts, J. A., & Lipman, J. (2011) · Critical Care · doi:10.1186/cc10262 · Cited by 211 · cited 2×
“[9], the authors showed that commonly used formulas used to calculate glomerular filtration rate usually underestimate creatinine (Cr) Cl.”
BackgroundMethodPharmacokinetics and Pharmacodynamics of Antimicrobials
Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/518137 · Cited by 194 · cited 12×
“AUC: area under the concentration time curve; bid: dose every 12 hours; CFR: cumulative fraction of response; Cl: drug clearance; Cr Cl: creatinine clearance; ELF: epithelial lining fluid; f: free drug fraction; Kel: elimination rate constant; MIC: minimum inhibitory concentration; MIC90: 90 th percentile of MIC in a…”
BackgroundInfluentialKasiakou, S. K., Sermaides, G. J., Michalopoulos, A., Soteriades, E. S., & Falagas, M. E. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70218-8 · Cited by 189
Roberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Dalley, A. J., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.008 · Cited by 188 · cited 12×
“…± 4.9 6.7 ± 4.2 3.7 ± 1.9 N = 6 Age 65.7 ± 11.2 years Peritonitis Descriptive Karjagin et al., 2008 [25] Meropenem 22.7 13.6 ± 1.3 NR N = 10 Age range 48 to 63 years Severe sepsis Randomized, parallel controlled Roberts et al., 2009 [24] Meropenem Meropenem 30.1 [21.7 to 53.9]e Meropenem 8 [5 to…”
BackgroundMethodInfluentialPharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia
Ariano, R. E., Nyhlén, A., Donnelly, J. P., Sitar, D. S., Harding, G. K., & Zelenitsky, S. A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e271 · Cited by 185
Roberts, J. A., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181968e44 · Cited by 183 · cited 13×
“…± 4.9 6.7 ± 4.2 3.7 ± 1.9 N = 6 Age 65.7 ± 11.2 years Peritonitis Descriptive Karjagin et al., 2008 [25] Meropenem 22.7 13.6 ± 1.3 NR N = 10 Age range 48 to 63 years Severe sepsis Randomized, parallel controlled Roberts et al., 2009 [24] Meropenem Meropenem 30.1 [21.7 to 53.9]e Meropenem 8 [5 to…”
BackgroundMethodInfluentialBenko, A. S., Cappelletty, D. M., Kruse, J. A., & Rybak, M. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.691 · Cited by 162 · cited 2×
“…= 7 mg/L (MIC90 of PA) T = 80% Kieft et al., 1993 [53] Ceftazidime 2 g tid or 3 g/day CI T > MIC MIC = 4 mg/L (MIC of one isolated PA) Bolus T = 92%; CI T = 100% Benko et al., 1996 [67] Ceftazidime 2 g tid or 60 mg/kg/day CI T > MIC (isolated pathogens) Bolus T = 92.9%; CI T = 100% Hanes et…”
BackgroundInfluentialSakka, S. G., Glauner, A. K., Bulitta, J. B., Kinzig-Schippers, M., Pfister, W., Drusano, G. L., & Sörgel, F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01318-06 · Cited by 159 · cited 2×
“, 2007 [31]”
BackgroundInfluentialJaruratanasirikul, S., Sriwiriyajan, S., & Punyo, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1337-1339.2005 · Cited by 149 · cited 19×
“AUC: area under the concentration time curve; bid: dose every 12 hours; CFR: cumulative fraction of response; Cl: drug clearance; Cr Cl: creatinine clearance; ELF: epithelial lining fluid; f: free drug fraction; Kel: elimination rate constant; MIC: minimum inhibitory concentration; MIC90: 90 th percentile of MIC in a…”
BackgroundMethodInfluentialMouton, J. W., Vinks, A. A. T. M. M., & Punt, N. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.733 · Cited by 142
Continuous infusion versus intermittent administration of meropenem in critically ill patients
Thalhammer, F., Traunmüller, F., Menyawi, I. E., Frass, M., Hollenstein, U., Locker, G. J., Stoiser, B., Staudinger, T., Thalhammer-Scherrer, R., & Burgmann, H. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.4.523 · Cited by 130 · cited 1×
“, 1999 [27]”
Boselli, E., Breilh, D., Duflo, F., Saux, M., Debon, R., CHASSARD, D., & Allaouchiche, B. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000069734.38738.c8 · Cited by 129 · cited 1×
“…[43] Piperacillin Bronchial secretions (tracheal aspirate) N = 8 VAP 0.36 Jehl et al., 1994 [42] Cefepime ELF (bronchoscopy) N = 20 VAP 1.04 (point concentration ratio) Boselli et al., 2003 [63] Cefepime or ceftazidime Bronchial secretions (tracheal aspirate) N = 5 cefepime VAP Cefepime < 0.02…”
InfluentialGentamicin volume of distribution in critically ill septic patients
Triginer, C., Izquierdo, I., Fernández, R., Rello, J., Torrent-Farnell, J., Benito, S., & Net, A. (1990) · Intensive Care Medicine · doi:10.1007/bf01706354 · Cited by 128 · cited 1×
“These pharmacokinetic (PK) changes are sometimes influenced by the clinical course of the infection itself [12].”
BackgroundBarbhaiya, R. H., Forgue, S. T., Gleason, C. R., Knupp, C. A., Pittman, K., Weidler, D. J., Movahhed, H., Tenney, J., & Martin, R. R. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.3.552 · Cited by 124
Nicasio, A. M., Ariano, R. E., Zelenitsky, S. A., Kim, A., Crandon, J. L., Kuti, J. L., & Nicolau, D. P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01141-08 · Cited by 123 · cited 1×
“…2 g tid Cefepime 20% PTA with 1 g every 4 hours 88.2% Cefepime 2 g tid 50% f T > MIC, with f assumed to be 85% PTA for MIC = 8 mg/L 91.8% Nicasio et al., 2009 [59] PTA for MIC = 32 mg/L 50.3% Cefepime 2 g (each 12 to 36 hours) 50% T > MIC MIC = 8 mg/L First dose 67%; steady-state 44%…”
BackgroundInfluentialRafati, M. R., Rouini, M. R., Mojtahedzadeh, M., Najafi, A., Tavakoli, H., Gholami, K., & Fazeli, M. R. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.02.020 · Cited by 120 · cited 1×
“…T = 20.3%, 500 mg qid 2 hours T = 17.7%, 1 g qid 2 hours T = 60.3% Piperacillin 3 g qid or 8 g/day CI T > MIC For MIC = 16 mg/L: bolus dosing T = 62%, CI T = 100% Rafati et al., 2006 [40] For MIC = 32 mg/L: bolus T = 39%, CI T = 65% Cefepime 2 g bid T > MIC MIC = 7 mg/L (MIC90 of PA) T = 80%…”
InfluentialIntermittent and continuous ceftazidime infusion for critically ill trauma patients
Hanes, S. D., Wood, G. C., Herring, V. L., Croce, M. A., Fabian, T. C., Pritchard, E., & Boucher, B. A. (2000) · The American Journal of Surgery · doi:10.1016/s0002-9610(00)00388-3 · Cited by 119 · cited 2×
“, 2000 [70]”
BackgroundInfluentialBuijk, S. L. C. E., Gyssens, I. C., Mouton, J. W., Vliet, A. V., Verbrugh, H. A., & Bruining, H. A. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.121 · Cited by 119 · cited 9×
“Continuous infusion, although theoretically useful, has not been shown to lead to improved outcomes.”
BackgroundInfluentialAntibiotic pharmacokinetic and pharmacodynamic considerations in critical illness
Mehrotra, R., Gaudio, R. D., & Palazzo, M. G. A. (2004) · Intensive Care Medicine · doi:10.1007/s00134-004-2428-9 · Cited by 117 · cited 1×
“Both Vd and drug clearance (Cl) may be increased in ICU patients [7].”
BackgroundAngus, B., Smith, M. D., Suputtamongkol, Y., Mattie, H., Walsh, A. L., Wuthiekanun, V., Chaowagul, W., & White, N. J. (2000) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2000.00179.x · Cited by 114
Lipman, J., Wallis, S. C., & Rickard, C. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.10.2559 · Cited by 114 · cited 6×
“-lactam antibioticsa (Continued) CI 100% Ceftazidime 1.5 g tid or 4.5 g/day CI T > 4 × MIC plasma and peritoneum (isolated pathogens) Plasma: bolus dosing 100%, CI 100% Buijk et al., 2002 [74] Peritoneum: bolus 88%, CI 100% Ceftazidime 2 to 6 g/day CI 100% T > 5 × MIC MIC = 8 mg/L (PA break point) Target concentration…”
BackgroundInfluentialGlomerular Hyperfiltration and Albuminuria in Critically ILL Patients
Fuster, Ó., Gerónimo‐Pardo, M., Peyró-García, R., & Lizán-García, M. (2008) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0803600507 · Cited by 109 · cited 1×
“This has recently been shown to be a common finding in ICU patients, particularly surgical and trauma patients [8] but also septic medical patients [9].”
BackgroundHow monitoring of the microcirculation may help us at the bedside
Verdant, C. L., & Backer, D. D. (2005) · Current Opinion in Critical Care · doi:10.1097/01.ccx.0000158849.94225.11 · Cited by 109 · cited 1×
“Moreover in ICU patients, maldistribution of blood flow in the microcirculation [10], namely, in patients in septic shock, may further decrease the drug concentration in the infected tissue [11].”
BackgroundPharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
Roos, J. F., Bulitta, J. B., Lipman, J., & Kirkpatrick, C. M. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl349 · Cited by 108 · cited 1×
“CFR according to Queensland Health Pathology Service CFR for EC: 2 g bid 78.9%, CI (4 g/day) 96.9% Roos et al., 2006 [60] CFR for PA: 2 g bid 54%, CI (4 g/day) 91.7% Ceftazidime 1 g every 4 hours 100% T > 4 × MIC (isolated pathogens; if negative cultures 100% T > 16 mg/L) Ceftazidime 47.8% PTA with…”
MethodInfluentialContinuous infusion ceftazidime in intensive care: a randomized controlled trial
Lipman, J., Gomersall, C. D., Gin, T., Joynt, G. M., & Young, R. J. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.2.309 · Cited by 107 · cited 5×
“-lactam antibioticsa (Continued) CI 100% Ceftazidime 1.5 g tid or 4.5 g/day CI T > 4 × MIC plasma and peritoneum (isolated pathogens) Plasma: bolus dosing 100%, CI 100% Buijk et al., 2002 [74] Peritoneum: bolus 88%, CI 100% Ceftazidime 2 to 6 g/day CI 100% T > 5 × MIC MIC = 8 mg/L (PA break point) Target concentration…”
BackgroundInfluentialPharmacokinetics and pharmacodynamics of meropenem in critically ill patients
Kitzes‐Cohen, R., Farin, D., Piva, G., & Myttenaere-Bursztein, S. A. D. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00474-5 · Cited by 104 · cited 3×
“001), despite a reduction in the dose administered, from 1 g every 8 h (tid) to 1 g every 12 h (bid) [21].”
BackgroundInfluentialProspective monitoring of cefepime in intensive care unit adult patients
Chapuis, T. M., Giannoni, É., Majcherczyk, P. A., Chioléro, R. L., Schaller, M., Berger, M. M., Bolay, S., Decosterd, L. A., Bugnon, D., & Moreillon, P. (2010) · Critical Care · doi:10.1186/cc8941 · Cited by 104 · cited 3×
“, 2010 [55] Gonçalves-Pereira and Póvoa Critical Care 2011, 15:R206”
BackgroundInfluentialChatellier, D., Jourdain, M., Mangalaboyi, J., Ader, F., Chopin, C., Derambure, P., & Fourrier, F. (2001) · Intensive Care Medicine · doi:10.1007/s00134-001-1170-9 · Cited by 102
Boselli, E., Breilh, D., Rimmele, T. R., Poupelin, J.-C., Saux, M., CHASSARD, D., & Allaouchiche, B. (2004) · Intensive Care Medicine · doi:10.1007/s00134-004-2171-2 · Cited by 96 · cited 2×
“…aspirate) N = 12 Nosocomial pneumonia 0.76 Bressolle et al., 1992 [77] Ceftazidime ELF (bronchoscopy) N = 15 VAP 0.21 (point concentration ratio at steady state) Boselli et al., 2004 [69] aELF: epithelial lining fluid; NR: not reported. bMean area under the concentration time curve (AUC)…”
BackgroundInfluentialTissue distribution of imipenem in critically ill patients
Tegeder, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122526 · Cited by 94 · cited 6×
“…31.4 ± 11.7 14.4 ± 4.5 1.6 ± 1.3 N = 10 Age 44 ± 12.2 years Severe sepsis Descriptive McKindley et al., 1996 [34] Imipenem 18.5 6.3 ± 0.8 2.0 N = 6 Age 63.5 ± 16.7 years Severe sepsis Not randomized, parallel, controlled Tegeder et al., 2002 [32] Imipenem 45.5 ± 47.2 12.1 ± 12.0 2.9 ± 1.7 N =…”
BackgroundInfluentialPharmacokinetic Evaluation of Meropenem and Imipenem in Critically Ill Patients with Sepsis
Novelli, A., Adembri, C., Livi, P., Fallani, S., Mazzei, T., & Gaudio, A. R. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544050-00007 · Cited by 93 · cited 4×
“, 2005 [29]”
InfluentialThe pharmacokinetics of the interstitial space in humans
Levitt, D. G. (2003) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-3-3 · Cited by 92
Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis
Joukhadar, C., Klein, N., Mayer, B. X., Kreischitz, N., Delle‐Karth, G., Palkovits, P., Heinz, G., & Müller, M. (2002) · Critical Care Medicine · doi:10.1097/00003246-200207000-00013 · Cited by 92 · cited 3×
“…et al., 1999 [47] Cefpirome 26.4 ± 7.9 8.8 ± 3.4 3.1 ± 1.2 N = 12 Age 41.2 ± 19 years Severe sepsis Descriptive Lipman et al., 2001 [48] Cefpirome 25.9 ± 7.1 4.5 ± 0.7 3.3 ± 0.5 N = 12 Age 67.2 ± 8.1 years Severe sepsis or septic shock Not randomized, parallel, controlled Joukhadar…”
BackgroundInfluentialIntermittent bolus dosing of ceftazidime in critically ill patients
Young, R. P., Lipman, J., Gin, T., Gomersall, C. D., Joynt, G. M., & Oh, T. E. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.2.269 · Cited by 90 · cited 2×
“, 1997 [65]”
Nicasio, A. M., Eagye, K. J., Nicolau, D. P., Shore, E. T., Palter, M. D., Pepe, J. L., & Kuti, J. L. (2009) · Journal of Critical Care · doi:10.1016/j.jcrc.2009.02.014 · Cited by 88
Boselli, E., Breilh, D., Rimmele, T. R., Guillaume, C., Xuereb, F., Saux, M., Bouvet, L., CHASSARD, D., & Allaouchiche, B. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318170ba21 · Cited by 86 · cited 1×
“…(point concentration ratio 5 hours after dose) Boselli et al., 2004 [41] Piperacillin ELF (bronchoscopy) N = 40 VAP 0.44 (point concentration ratio 4 hours after dose) Boselli et al., 2008 [43] Piperacillin Bronchial secretions (tracheal aspirate) N = 8 VAP 0.36 Jehl et al., 1994 [42] Cefepime…”
BackgroundInfluentialCefepime Versus Cefpirome: The Importance of Creatinine Clearance
Lipman, J., Wallis, S. C., & Boots, R. J. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000077077.54084.b0 · Cited by 85
Altered Pharmacokinetics of Ceftazidime in Critically Ill Patients
Gómez, C. M., Cordingly, J. J., & Palazzo, M. G. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1798 · Cited by 81 · cited 1×
“, 1999 [66]”
Principles of Antibacterial Dosing in Continuous Renal Replacement Therapy
Choi, G. Y. S., Gomersall, C. D., Tian, Q., Joynt, G. M., Li, A. M. M. Y., & Lipman, J. (2010) · Blood Purification · doi:10.1159/000321488 · Cited by 79 · cited 1×
“Furthermore, a full revision of those studies has recently been published [17].”
BackgroundKarjagin, J., Lefeuvre, S., Oselin, K., Kipper, K., Marchand, S., Tikkerberi, A., Starkopf, J., Couet, W. R., & Sawchuk, R. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100312 · Cited by 79 · cited 5×
“74 in the peritoneum [25] and 0.”
BackgroundInfluentialMultiple-dose pharmacokinetics of imipenem-cilastatin
Drusano, G. L., Standiford, H. C., Bustamante, C. I., Forrest, A., Rivera, G., Leslie, J. L., Tatem, B. A., Delaportas, D., MacGregor, R. R., & Schimpff, S. C. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.5.715 · Cited by 79 · cited 1×
“healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of”
BackgroundBoselli, E., Breilh, D., Cannesson, M. P., Xuereb, F., Rimmele, T. R., CHASSARD, D., Saux, M., & Allaouchiche, B. (2004) · Intensive Care Medicine · doi:10.1007/s00134-004-2222-8 · Cited by 77 · cited 2×
“…aspirate) N = 12 Nosocomial pneumonia 0.76 Bressolle et al., 1992 [77] Ceftazidime ELF (bronchoscopy) N = 15 VAP 0.21 (point concentration ratio at steady state) Boselli et al., 2004 [69] aELF: epithelial lining fluid; NR: not reported. bMean area under the concentration time curve (AUC)…”
BackgroundInfluentialPharmacokinetics and Pharmacodynamics of Cefpirome in Subcutaneous Adipose Tissue of Septic Patients
Sauermann, R., Delle‐Karth, G., Marsik, C. L., Steiner, I. M., Zeitlinger, M. A., Mayer‐Helm, B., Georgopoulos, A. P., Müller, M., & Joukhadar, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.650-655.2005 · Cited by 71 · cited 4×
“…0.63 Volunteers 0.83 Joukhadar et al., 2002 [52] Cefpirome Microdialysis in subcutaneous tissue N = 18 (11 patients) Severe sepsis Patients 0.43 Volunteers 0.79 Sauermann et al., 2005 [51] Burned skin Cefepime Biopsy of burned area N = 6 Burn patients Day 3 1.52 (point concentration 3 to 5…”
BackgroundInfluentialParadis, D., Vallée, F., Allard, S., Bisson, C., Daviau, N., Drapeau, C., Auger, F. A., & LeBel, M. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.10.2085 · Cited by 70 · cited 1×
“healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of”
BackgroundLipman, J., Wallis, S. C., Rickard, C. M., & Fraenkel, D. J. (2001) · Intensive Care Medicine · doi:10.1007/s001340000741 · Cited by 69 · cited 3×
“, 2001 [48]”
InfluentialSerum markers in community-acquired pneumonia and ventilator-associated pneumonia
Póvoa, P. M. S. R. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f47c32 · Cited by 68 · cited 1×
“However, the efficacy of antibiotics is not easily evaluated, since the clinical response is usually unnoticeable before 48 hours of therapy [3].”
BackgroundSelf-citationConil, J., Georges, B., Mimoz, O., Dieye, E., Ruiz, S., Cougot, P., Samii, K., Houin, G., & Saivin, S. (2006) · Intensive Care Medicine · doi:10.1007/s00134-006-0421-1 · Cited by 63
Mouton, J. W., Punt, N. C., & Vinks, A. A. T. M. M. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.013 · Cited by 63
Bourget, P., Lesne-Hulin, A., Reveille, R. L., Bever, H. L., & Carsin, H. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.1.139 · Cited by 58 · cited 2×
“, 1996 [38]”
InfluentialPharmacodynamic optimization of β-lactams in the patient care setting
Nicolau, D. P. (2008) · Critical Care · doi:10.1186/cc6818 · Cited by 57
Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men
Ljungberg, B., & Nilsson-Ehle, I. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.7.1437 · Cited by 56 · cited 1×
“healthy volunteers [44,51,89-92]; filled squares: weighted means of volume of distribution in the studies; straight lines: ranges of the means of”
BackgroundGentamicin dosing in critically ill patients
Hansen, M., Christrup, L. L., Jarløv, J. O., Kampmann, J. P., & Bonde, J. (2001) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.2001.045006734.x · Cited by 56 · cited 1×
“Consequently, PK parameters measured in healthy volunteers may not correctly predict concentrations in septic ICU patients, particularly early in the course of a severe infection [13,14].”
BackgroundRhomberg, P. R., & Jones, R. N. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.07.009 · Cited by 53 · cited 1×
“The meropenem CFR was calculated for the 10 patients for whom serum levels were measured in this study according to the Mystic microbiological database [26].”
MethodConil, J., Georges, B., Lavit, M., Seguin, T., Tack, I., Samii, K., Chabanon, G., Houin, G., & Saivin, S. (2007) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp45529 · Cited by 52 · cited 1×
“, 2007 [54]”
Shah, P. M. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01868.x · Cited by 52 · cited 1×
“High Vd and Cl have usually been reported, as well as a low binding fraction: < 10% [18].”
BackgroundImpact of pharmacodynamics on breakpoint selection for susceptibility testing
Mouton, J. W. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00062-x · Cited by 51 · cited 12×
“AUC: area under the concentration time curve; bid: dose every 12 hours; CFR: cumulative fraction of response; Cl: drug clearance; Cr Cl: creatinine clearance; ELF: epithelial lining fluid; f: free drug fraction; Kel: elimination rate constant; MIC: minimum inhibitory concentration; MIC90: 90 th percentile of MIC in a…”
BackgroundMethodInfluentialImipenem Levels Are Not Predictable in the Critically Ill Patient
Belzberg, H., Zhu, J., Cornwell, E. E., Murray, J., Sava, J. A., Salim, A., Velmahos, G. C., & Gill, M. A. (2004) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/01.ta.0000056164.26493.28 · Cited by 51 · cited 2×
“…± 0.8 2.0 N = 6 Age 63.5 ± 16.7 years Severe sepsis Not randomized, parallel, controlled Tegeder et al., 2002 [32] Imipenem 45.5 ± 47.2 12.1 ± 12.0 2.9 ± 1.7 N = 50 Age 45.2 ± 17 years Presumed Gramnegative sepsis Cross-sectional Belzberg et al., 2004 [28] Penicillins Piperacillin 25.0 ± 17.2…”
BackgroundInfluentialReview of Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents
Estes, L. L. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.11.1114 · Cited by 47 · cited 1×
“Drugs that distribute essentially in the extracellular fluid (mainly hydrophilic) have low Vd, whilst drugs that have rapid cellular uptake (lipophilic) have high Vd[5,6].”
BackgroundRoos, J. F., Lipman, J., & Kirkpatrick, C. M. J. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0573-7 · Cited by 46 · cited 1×
“CFR according to EUCAST database CFR for EC: bolus 99.9%, CI (4 g/day) 100% Roos et al., 2007 [50] CFR for PA: bolus 56.1%, CI (4 g/day) 84.4% Cefepime 2 g 60% T > MIC MIC = 8 mg/L (NCCLS break point of PA) PTA with 1 g bid 45% PTA with 2 g bid 68% Bonapace et al., 1999 [57] PTA for MIC = 4 mg/L: 1…”
MethodInfluentialBressolle, F., COUSSAYE, J. E. D. L., Ayoub, R., Fabre, D., Goméni, R., Saïssi, G., Eledjam, J., & Galtier, M. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.7.1404 · Cited by 46 · cited 4×
“Table 3 Tissue penetration of b-lactamsa Antibiotics Samples Patient demographics Concentration ratiosb References Muscle and subcutaneous tissue Meropenem Microdialysis in subcutaneous tissue N = 10 severe sepsis, 5 continuous infusion Bolus 0.44 Continuous infusion 0.57 (day 2) Roberts et al., 2009 [24] Imipenem Mic…”
InfluentialGeorges, B., Conil, J., Seguin, T., Ruiz, S., Minville, V., Cougot, P., Decun, J. F., Gonzalez, H., Houin, G., Fourcade, O., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00430-09 · Cited by 45
Pharmacokinetics of cefepime in patients with the sepsis syndrome
Kieft, H., Hoepelman, A. I. M., Knupp, C. A., van Dijk, A. P. J., Branger, J., Struyvenberg, A., & Verhoef, J. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.suppl_b.117 · Cited by 43 · cited 3×
“…Not randomized, parallel, controlled Joukhadar et al., 2002 [52] Cefpirome 21.9 ± 4.5 4.8 ± 1.6 3.1 ± 0.9 N = 11 Age 66 ± 8 years Severe sepsis Not randomized, parallel, controlled Sauermann et al., 2005 [51] Cefepime 32.6 ± 17.5 7.5 ± 3.1 3.5 ± 1.1 N = 7 Age 73.7 ± 4.9 years Severe…”
InfluentialProspective Determination of Serum Ceftazidime Concentrations in Intensive Care Units
Aubert, G., Carricajo, A., Coudrot, M., Guyomarch, S., Auboyer, C., & Zéni, F. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181e60ca6 · Cited by 40 · cited 1×
“…[74] Peritoneum: bolus 88%, CI 100% Ceftazidime 2 to 6 g/day CI 100% T > 5 × MIC MIC = 8 mg/L (PA break point) Target concentration 40 ± 10 mg/ L 35.9% Aubert et al., 2010 [72] Percentage of time on target (mean) Meropenem 2 g tid or 3 g CI T > MIC (isolated susceptible pathogens) Bolus T =…”
BackgroundInfluentialPharmacokinetics of Aztreonam and Imipenem in Critically Ill Patients with Pneumonia
McKindley, D. S., Boucher, B. A., Hess, M. M., Croce, M. A., & Fabian, T. C. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb03010.x · Cited by 40 · cited 3×
“…(point concentration ratio 2 hours after dose) Muller-Serieys et al., 1987 [35] Imipenem Bronchial secretions (tracheal aspirate) N = 10 Trauma patients with VAP NR McKindley et al., 1996 [34] Piperacillin ELF (bronchoscopy) N = 10 VAP 0.57 (point concentration ratio 5 hours after dose)…”
BackgroundInfluentialApplication of Basic Pharmacokinetic Concepts to Analysis of Microdialysis Data
Dahyot, C., Marchand, S., Bodin, M., Debeane, B., Mimoz, O., & Couet, W. R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847030-00004 · Cited by 36 · cited 3×
“Table 3 Tissue penetration of b-lactamsa Antibiotics Samples Patient demographics Concentration ratiosb References Muscle and subcutaneous tissue Meropenem Microdialysis in subcutaneous tissue N = 10 severe sepsis, 5 continuous infusion Bolus 0.44 Continuous infusion 0.57 (day 2) Roberts et al., 2009 [24] Imipenem Mic…”
BackgroundInfluentialPharmacokinetics of Cefepime in Patients with Thermal Burn Injury
Bonapace, C. R., White, R. L., Friedrich, L. V., Norcross, E. D., & Bosso, J. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2848 · Cited by 36 · cited 3×
“…et al., 2007 [50] CFR for PA: bolus 56.1%, CI (4 g/day) 84.4% Cefepime 2 g 60% T > MIC MIC = 8 mg/L (NCCLS break point of PA) PTA with 1 g bid 45% PTA with 2 g bid 68% Bonapace et al., 1999 [57] PTA for MIC = 4 mg/L: 1 g bid 68%, 2 g bid 89% Cefepime 2 g 65% f T > MIC, with f assumed to be 90%.”
BackgroundInfluentialThe pharmacokinetics of meropenem in surgical patients with moderate or severe infections
Lovering, A. M., Vickery, C. J., Watkin, D. S., Leaper, D. J., McMullin, C. M., White, L. O., Reeves, D. S., & MacGowan, A. P. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.1.165 · Cited by 31 · cited 3×
“One study addressed the variability of individual meropenem PK between the first and fourth days of therapy in 11 surgical patients [22].”
BackgroundInfluentialLanggartner, J., Lehn, N., Glück, T., Herzig, H., & Kees, F. (2007) · Chemotherapy · doi:10.1159/000107725 · Cited by 29 · cited 2×
“, 2007 [39]”
InfluentialPlasma, urine and skin pharmacokinetics of cefepime in burns patients
Sampol, E., Jacquet, A., Viggiano, M., Bernini, V., Manelli, J. C., Lacarelle, B., & Durand, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.315 · Cited by 28 · cited 3×
“…21.8 ± 5.1 7.6 ± 2.0 3 ± 1.2 N = 13 Age 55 years Severe sepsis Descriptive Lipman et al., 1999 [56] Cefepime 36.1 ± 11.8 8.8 ± 2.4 2.8 ± 0.6 N = 12 Age 41 ± 13 years Burn patients Descriptive Bonapace et al., 1999 [57] Cefepime 26.0b 9.1 ± 1.5b 2.5 ± 0.6b N = 6 Age 39.8 ± 11.3 years…”
BackgroundInfluentialJaruratanasirikul, S., & Sudsai, T. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn543 · Cited by 28 · cited 2×
“9 years VAP Not randomized, controlled, cross-over Jaruratanasirikul and Sudsai, 2009 [30]”
BackgroundInfluentialGentry, L. O., & Rodriguez-Gomez, G. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.11.2371 · Cited by 26
Effects of treatment and the metabolic response to injury on drug clearance
Shikuma, L. R., Ackerman, B. H., Weaver, R. H., Solem, L. D., Strate, R. G., Cerra, F. B., & Zaske, D. E. (1990) · Critical Care Medicine · doi:10.1097/00003246-199001000-00010 · Cited by 21 · cited 2×
“, 1990 [36]”
InfluentialEffectiveness of Cephalosporins in the Sputum of Patients with Nosocomial Bronchopneumonia
Klekner, Á., Bágyi, K., Bognár, L., Gáspár, A., Andrási, M., & Szabó, J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00893-06 · Cited by 21 · cited 1×
“…= 20 VAP 1.04 (point concentration ratio) Boselli et al., 2003 [63] Cefepime or ceftazidime Bronchial secretions (tracheal aspirate) N = 5 cefepime VAP Cefepime < 0.02 Klekner et al., 2006 [62] N = 4 ceftazidime VAP Ceftazidime < 0.05 Ceftazidime Bronchial secretions (tracheal aspirate) N = 5…”
InfluentialMeropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia
de Stoppelaar, F. M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.1.150 · Cited by 19 · cited 2×
“…T > MIC (isolated susceptible pathogens) Bolus T = 100%; CI T = 100% Thalhammer et al., 1999 [27] Meropenem 1 g tid T > MIC (isolated pathogens) T = 90.8% de Stoppelaar et al, 2000 [19] T > 4 × MIC T = 52% Meropenem 1 g bid or 1 g tid T > MIC (isolated pathogens) T = 80.9% (Cr Cl > 50 mL/minute; 1…”
BackgroundInfluentialJehl, F., Muller‐Serieys, C., de Larminat, V., Monteil, H., & Bergogne-Bérézin, E. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.12.2780 · Cited by 18 · cited 1×
“…N = 40 VAP 0.44 (point concentration ratio 4 hours after dose) Boselli et al., 2008 [43] Piperacillin Bronchial secretions (tracheal aspirate) N = 8 VAP 0.36 Jehl et al., 1994 [42] Cefepime ELF (bronchoscopy) N = 20 VAP 1.04 (point concentration ratio) Boselli et al., 2003 [63] Cefepime…”
InfluentialGeorges, B., Jm, C., Seguin, T., Dieye, E., Cougot, P., Decun, J. F., Lavit, M., Samii, K., Houin, G., & Saivin, S. (2008) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp46157 · Cited by 17
Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome
Jacolot, A., Incagnoli, P., Edouard, A. R., Tod, M. M., Petitjean, O., Samii, K., & Mimoz, O. (1999) · Intensive Care Medicine · doi:10.1007/s001340050885 · Cited by 14 · cited 3×
“…11.7f 17.2 0.4 N = 13 Age 37.5 ± 19.4 years Severe sepsis Randomized, parallel, controlled Roberts et al., 2009 [45] Cephalosporins Cefpirome 23.6 ± 8.0 8.0 ± 3.0 2.2 ± 0.5 N = 9 Age 31 years [19 to 53] Severe sepsis Not randomized, parallel, controlled Jacolot et al., 1999…”
InfluentialImipenem penetration into bronchial secretions
Muller‐Serieys, C., Bergogne-Bérézin, E., ROWAN, C., & Dombret, M.-C. (1987) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/20.4.618 · Cited by 14 · cited 1×
“…2 • Continuous infusion 0.56 Buijk et al., 2002 [74] • Bolus 0.35 Imipenem ELF (bronchoscopy) N = 8 Pneumonia 0.20 (point concentration ratio 2 hours after dose) Muller-Serieys et al., 1987 [35] Imipenem Bronchial secretions (tracheal aspirate) N = 10 Trauma patients with VAP NR McKindley…”
BackgroundInfluentialCeftazidime in the treatment of Pseudomonas infections in intensive-care patients.
Rondanelli, R., Dionigi, R., Regazzi, M. B., Maurelli, M., Calvi, M., & Mapelli, A. (1986) · PubMed · Cited by 10
Penetration of ceftazidime into bronchial secretions in critically ill patients
Langer, M., Cantoni, P., Bellosta, C., & Boccazzi, A. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.6.925 · Cited by 7 · cited 2×
“, 1991 [76]”
Influential
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
BackgroundAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
“acyclovir, aminoglycosides, beta-lactams, daptomycin, fluconazole and glycopeptides), this can result in a significantly expanded Vd [7].”
Background
Metadata
- Authors
- Gonçalves-Pereira, J., & Póvoa, P.
- Affiliations
- University of Lisbon (PT)
- ORCID
- Póvoa, Pedro
- Venue
- Critical Care
- Published
- 2011-09-13
- Volume
- 15
- Issue
- 5
- Pages
- R206-R206
- ISSN
- 1364-8535 (ISSN-L)
- PMC
- PMC3334750
- OpenAlex
- W2070242840
- Semantic Scholar
- 028a21fcf10a276ab1fc87191ee4ae66b704ce5e
- Cited by
- 408
- References
- 93
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 26 · 2023: 36 · 2022: 32 · 2021: 43 · 2020: 27 · 2019: 22 · 2018: 24 · 2017: 25 · 2016: 27 · 2015: 26 · 2014: 31 · 2013: 17 · 2012: 21
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Critical Care (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, antibiotic pharmacokinetics, critically ill patients, intensive care unit, volume of distribution, drug clearance, creatinine clearance, half-life, time above MIC, pharmacodynamics, continuous infusion, septic shock, tissue penetration, therapeutic drug monitoring, antibiotic dosing, meropenem, imipenem, piperacillin, cefpirome, cefepime, ceftazidime
- MeSH terms
- Cefepime, Meropenem, Cefpirome, Anti-Bacterial Agents, Ceftazidime, Cephalosporins, Humans, Infections, Piperacillin, Thienamycins, Imipenem, Critical Illness, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.